Janagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor under development for the treatment of metabolic disorders, particularly type 2 diabetes mellitus. It is designed to reduce renal glucose reabsorption, thereby increasing urinary glucose excretion and lowering blood glucose levels.
Janagliflozin is a specialized antidiabetic pharmaceutical API manufactured through controlled chemical synthesis, purification and crystallization.
Important quality attributes include identity, assay, related substances, water content, residual solvents, elemental impurities, residue on ignition, polymorphic form and stability.
CAS Number: 2377614-95-2
Molecular Formula: C24H27ClO7
Molecular Weight: 462.92 g/mol
Drug Class: Antidiabetic Agent
Pharmacological Class: SGLT2 Inhibitor
Therapeutic Class: Sodium-Glucose Cotransporter-2 Inhibitor
Therapeutic Area: Endocrinology / Metabolic Disorders
Janagliflozin selectively inhibits SGLT2, a transporter responsible for most renal glucose reabsorption in the proximal renal tubules.
SGLT2 inhibition:
Janagliflozin is being investigated primarily for:
As an investigational/development-stage compound in some markets, its approved indications and regulatory status should be confirmed for the applicable jurisdiction.
Janagliflozin belongs to the gliflozin class of glucose-lowering agents. Its mechanism is independent of insulin secretion and instead acts through the kidney by increasing glucose elimination in urine.
Typical API manufacturing may involve:
Janagliflozin API quality evaluation may include:
Janagliflozin should be stored in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive heat, moisture and direct light. Final storage conditions should be established through validated stability studies.
Janagliflozin is relevant to research involving:
Janagliflozin is an SGLT2 inhibitor with CAS Number 2377614-95-2, molecular formula C24H27ClO7, and molecular weight 462.92 g/mol. It acts by inhibiting renal glucose reabsorption and increasing urinary glucose excretion, making it relevant to type 2 diabetes and metabolic-disease research.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |